Credit Suisse analyst Richard Law upgraded C4 Therapeutics (NASDAQ: CCCC) from Underperform to Neutral with a price target of $10.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Upgrades

C4 Therapeutics (CCCC) PT Lowered to $8 at StifelFebruary 24, 2023 8:41 AM C4 Therapeutics (CCCC) PT Lowered to $22 at UBSFebruary 24, 2023 7:18 AM JPMorgan Downgrades C4 Therapeutics (CCCC) to UnderweightFebruary 24, 2023 2:19 AM Form 8-K/A C4 Therapeutics, Inc. For: Feb 23February 23, 2023 4:20 PM Form S-8 C4 Therapeutics, Inc. February 23, 2023 4:18 PM Form POS AM C4 Therapeutics, Inc. February 23, 2023 4:12 PM Form 10-K C4 Therapeutics, Inc. For: Dec 31February 23, 2023 8:54 AM Form POSASR C4 Therapeutics, Inc. February 23, 2023 8:34 AM C4 Therapeutics, Inc. (CCCC) Misses Q4 EPS by 188cFebruary 23, 2023 7:51 AM Form 8-K C4 Therapeutics, Inc. For: Feb 23February 23, 2023 7:42 AM C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business HighlightsFebruary 23, 2023 7:00 AM